biotech
(4)
SynOx Therapeutics Secures $75m For Phase 3 TGCT Treatment Trial
SynOx Therapeutics, a late-stage clinical biopharmaceutical company, has concluded a $75 million Series B financing, co-led by Forbion, HealthCap, and Bioqube Ventures. The funding aims to propel the registrational Phase 3 clinical and CMC data gener...
Orson Amiri · 23 April · 1
Natural Food Additives: Enhancing Flavor, Texture, and Preservation with Nature's Goodness
In the quest for delectable and wholesome food, natural food additives have emerged as a valuable tool. These substances, derived from plants, animals, or minerals, are added to food to enhance its flavor, texture, appearance, preservation, or nutrit...
Rachel · 25 December 2023 · 3
Based on Antibody Targeted Protein Degradation
In recent years, PROteolysis TArgeting Chimeras (PROTAC), which utilizes the cell's own degradation mechanisms to eliminate specific disease-related proteins, has emerged as one of the most promising methods. Apart from PROTAC, various targeted protein degradation (TPD) strategies are emerging, involving molecular glue, Autophagy-Targeting Chimera...
Krystal Beily · 31 October 2023 · 1Complete 3D Structure of P53 Protein Found
The tumor suppressor protein p53, known as the "guardian of the genome," protects the body's DNA from daily stress or long-term damage by triggering cells to either repair or self-destruct. But mutations in the p53 gene that codes for this protein prevent it from working, allowing errors to accumulate in the genetic code, leading to diseases such a...
ruiqi tu · 16 August 2023 · 2